Phase 4 N=42 Endogenous Opioid Activity and Affective State in Insulin Resistant Women
Depression · Insulin Resistance · Metabolic Syndrome
Primary: Mu-opioid Receptor Binding Potential in Left Nucleus Accumbens, Resting State
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=50 Valproate for Mood Swings and Alcohol Use Following Head Injury
Traumatic Brain Injury (TBI) · Alcoholism
Primary: Severity of Affective Lability Based on Shortened Agitated Behavior Scale — 9.22; 9.39 units on a scale
N/A N=108 Cognitive and Emotional Skills to Aid Smoking Prevention
Tobacco Smoking
Primary: Specific Aim 1: Percentage of Participants Who Attended 13 or More Interventions — 41.0; 50; 40.5 percentage of participants
Phase 4 N=95 Connectivity Affecting the Antidepressant REsponse Study
Major Depressive Disorder
Primary: Number of Patients With Remission of Depression — 37; 13 Participants — p=0.0689
Phase 2 N=775 Project 3, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in People With Current Affective Disorders
Tobacco Use Disorder
Primary: Cigarettes Per Day (CPD) — 25.28; 19.95; 17.74 cigarettes per day — p=<0.0001
N/A N=4 Novel Brain Signal Feedback Paradigm to Enhance Motor Learning After Stroke
Stroke
Primary: Arm Motor Abilities Test Functional Domain (AMAT - F) — .54 units on a scale
N/A N=10 Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression
Postpartum Depression
Primary: Number of Successfully Analyzed EEG Recordings — 49 EEG recordings
N/A N=103 Developing Genetic Education for Smoking Cessation
Tobacco Smoking
Primary: Knowledge of Genetic Contributions to Smoking — 5.25; 3.73; 7.04; 4.03 score on a scale — p=<0.01
Phase 4 N=60 Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety
Anxiety Disorder
Primary: Magnitude of Startle Reflex During Safe Condition — 42.2880893; 42.39801; 43.61243; 44.1886408 millivolts (mV)
N/A N=46 Targeting Self-regulatory Deficits Through Cognitive Remediation Intervention
Drug Use Disorders
Primary: Change in Stop Signal Reaction Time — -8.62 ms — p=.003
Phase 2 N=58 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders
Mood Disorder · Disruptive Behavior Disorders
Primary: Change in Affective Reactivity Index - Youth (ARI-Y) — -2.9; -0.8 score on a scale
Phase 4 N=50 Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder
Seasonal Affective Disorder
Primary: Sleep Satisfaction at Baseline and Measured Monthly, as Measured by the Pittsburgh Sleep Quality Index (PSQI) — 11.56; 11.45; 9.52; 8.67 scores on a scale
Phase 3 N=106 A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD)
Seasonal Affective Disorder
Primary: Percentage Change SIGH SAD Depression Rating — -36.4; -52.7 percentage of change on SIGH SAD — p=0.014
Phase 1 N=61 Cognitive Behavioral Therapy for the Treatment of Seasonal Affective Disorder (SAD)
Seasonal Affective Disorder · Depression
Primary: Scores on the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version — 13.6; 13.3; 8.3; 22.6 units on a scale
Early Phase 1 N=30 Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation
Renal Disease · Sleep Disorders
Primary: Bedtime — 7.44; 7.24; 22.98; 22.48 Hours